Experimental methods are commonly used for patient-specific intensitymodulated radiotherapy (IMRT) verification. The purpose of this study was to investigate the accuracy and performance of independent dose calculation software (denoted as 'MUV' (monitor unit verification)) for patient-specific quality assurance (QA). 52 patients receiving step-and-shoot IMRT were considered. IMRT plans were recalculated by the treatment planning systems (TPS) in a dedicated QA phantom, in which an experimental 1D and 2D verification (0.3 cm 3 ionization chamber; films) was performed. Additionally, an independent dose calculation was performed. The fluence-based algorithm of MUV accounts for collimator transmission, rounded leaf ends, tongueand-groove effect, backscatter to the monitor chamber and scatter from the flattening filter. The dose calculation utilizes a pencil beam model based on a beam quality index. DICOM RT files from patient plans, exported from the TPS, were directly used as patient-specific input data in MUV. For composite IMRT plans, average deviations in the high dose region between ionization chamber measurements and point dose calculations performed with the TPS and MUV were 1.6 ± 1.2% and 0.5 ± 1.1% (1 S.D.). The dose deviations between MUV and TPS slightly depended on the distance from the isocentre position. For individual intensity-modulated beams (total 367), an average deviation of 1.1 ± 2.9% was determined between calculations performed with the TPS and with MUV, with maximum deviations up to 14%. However, absolute dose deviations were mostly less than 3 cGy. Based on the current results, we aim to apply a confidence limit of 3% (with respect to the prescribed dose) or 6 cGy for routine IMRT verification. For off-axis points at distances larger than 5 cm and for low dose regions, we consider 5% dose deviation or 10 cGy acceptable. The time needed for an independent calculation compares very favourably with the net time for an experimental approach. The physical effects modelled in the dose calculation software MUV allow accurate dose calculations in individual verification points. Independent calculations may be used to replace experimental dose verification once the IMRT programme is mature.
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Introduction
IMRT has made a considerable impact on both clinical and physical aspects of radiotherapy. From the very beginning, the importance of IMRT specific QA procedures has been emphasized and the clinical requirements for IMRT implementation have been the driving force behind many medical physics research activities. A major difficulty with designing IMRT QA procedures for treatment delivery units, TPS and patient-specific QA was that the likely failures for this new treatment technique were not known. On the other hand, traditionally used methods and equipment that were designed for dose verification in uniform intensity beams were becoming obsolete. For example, point dose measurements were replaced or supplemented with two-dimensional measurements (e.g. Stock et al 2005 , Wiezorek et al 2005 . Another example is monitor unit (MU) verification procedures, as empirical methods for dose calculation (Dutreix et al 1997 , Mijnheer et al 2004 cannot be applied or extended to IMRT in any straightforward manner.
Due to the lack of efficient tools for patient-specific QA, experimental methods were, and still are, commonly used to verify IMRT treatment plans. For this purpose, a vast variety of dosimetric approaches is applied (Chen et al 2005 , Ezzell et al 2003 , Gillis et al 2005 , Van Esch et al 2004 , Winkler et al 2005 , Low et al 1998 . Experimental methods are, however, time consuming for the physicist and they do also require accelerator time. As inverse planning becomes more efficient and the number of IMRT cases and indications is likely to increase continuously, experimental IMRT verification may risk becoming the bottleneck in the clinical workflow.
Independent dose calculations offer an alternative to experimental methods. Kung et al (2000) and Chen et al (2002) have published early papers on independent MU calculation for IMRT. The algorithms these authors proposed are very similar to traditional empiricalfactor-based methods, i.e. based on measured input data relating different beam conditions with the calibration geometry. Commonly, the phantom scatter part was calculated with a modified Clarkson integration (Clarkson 1941) and the calculation points were limited to the central axis. The head scatter was derived from equivalent square approaches considering the secondary collimator jaw settings only. Watanabe (2001) introduced an analytical pencil beam kernel for IMRT plan checking, but its head scatter calculation was explicitly mentioned as an accuracy limitation. Yang et al (2003) pointed out that accurate head scatter modelling is very important when verifying the dose per given MU of IMRT treatment plans, particularly at off-axis positions. Finally, algorithms have been described for dose verification related to dedicated equipment. Chen et al (2002) proposed an independent MU calculation formalism for serial tomotherapy, whereas Linthout et al (2004) presented an algorithm that was designed for IMRT delivery on a linear accelerator with an integrated mini-multileaf collimator (MLC).
Their procedure based on an empirical formalism was embedded in an Excel spreadsheet program and did not separate head scatter from phantom scatter effects. Recently, commercial software has become available for MU verification including IMRT and dynamic wedges. However, little information can be found in the literature about their clinical application, the type of algorithms that are utilized and the accuracy that can be obtained.
Many of the above-cited independent dose and MU verification algorithms have been validated with IMRT delivery techniques that utilize an add-on MLC located beyond the secondary jaw collimator. For these types of MLCs, the head scatter variation with the field size is mainly defined by the secondary collimator jaw settings whereas for other types of MLCs, where the upper or the lower pair of jaws are replaced by leaves, head scatter can be largely influenced by the leaf setting (Georg et al 2004 , Naqvi et al 2001 , Hounsell and Wilkinson 1997 . Consequently, any dose calculation algorithm for such MLC types needs a sophisticated head scatter model in order to achieve a high accuracy. Additionally, the verification algorithm should provide high accuracy irrespective of the particular radiotherapy equipment in use, and should allow easy commissioning based on independent input data. For practical reasons, the measured data sets should be as small and simple to acquire as possible.
The purpose of this study was to investigate the accuracy and performance of the independent dose calculation software 'MUV' (monitor unit verification) for IMRT verification. Within the present study, 52 IMRT plans have been evaluated both by experimental methods and by the MUV software to investigate the feasibility of replacing the experimental monitor unit verification procedures by semi-analytical calculation methods in the MUV software. These evaluations have been performed on both the beam axis and the off-axis. Finally, workload aspects associated with IMRT verification are briefly discussed.
Methods and materials

MUV software
The semi-analytical model implemented in MUV is based on two components calculated in separate steps: (i) the energy fluence per MU exiting the treatment head and (ii) calculation of dose deposition in the phantom due to the energy fluence from the previous step. The multi-source model describing the energy fluence takes into account the direct (focal) energy fluence, scattered photons from extra-focal sources, as well as backscattered radiation to the monitor chamber. The effects of collimator transmission, leakage in rounded leaf ends and tongue and groove at the leaf sides are also taken into account. The subsequent dose deposition calculation is based on a pencil beam model, solely characterized by the beam quality index TPR 20, 10 . Details of the calculation models implemented in the software MUV have been published previously (Olofsson et al 2003 (Olofsson et al , 2006a (Olofsson et al , 2006b Nyholm et al 2006a Nyholm et al , 2006b ). The current version does not support simultaneous calculations in more than one point of interest.
Treatment plans
Plans for 52 patients to receive step-and-shoot IMRT with an ELEKTA linac (1 cm projected leaf width at the isocentre distance) were used as test cases. Out of these, 33 plans were optimized with Helax TMS (V6.1B) and 19 plans with Oncentra Masterplan (V1.4.3.1, Nucletron, The Netherlands). IMRT plans were based on a seven field arrangement except for five plans which had five or nine fields. In total, 367 intensity-modulated beams (IMB) were included in the analysis. During treatment plan optimization, the number of intensity levels per beam was restricted to 10. The number of segments per beam varied between 5 and 15.
The treatment plans comprised 38 head-and-neck cases, 12 pelvic cases (prostate and gynaecology) and 2 lung cases. Out of the 38 head-and-neck cases, 13 patients received an IMRT plan with a simultaneous integrated boost (SIB) with two dose levels (50 Gy and 60 Gy), and 2 with three different dose levels (54, 60 and 70 Gy).
Verification procedures
After an IMRT treatment plan was accepted, it was recalculated using identical beam settings but replacing the patient with a dedicated solid polystyrene QA phantom. We used phantoms with octagonal cross sections, for head-and-neck IMRT plans of size 20 × 20 × 18 cm 3 , whereas for pelvic and lung cases a larger phantom of size 35 × 22.5 × 24 cm 3 was used. Both phantoms were equipped with a special insert to accommodate an ionization chamber (IC), type NE 2611 (volume 0.3 cm 3 , Nuclear Enterprises, UK) in its centre. Additionally, 2D verification can be performed in axial slices with film. The experimental verification procedures and results for composite treatment plans have been described earlier (Stock et al 2005 , Georg et al 2003 . The patient plan was copied onto the respective verification phantom in such a way that the IC was located in a high dose region with no or just a small dose gradient (<5% cm −1 ). By verifying a point of interest with an ionization chamber in a flat dose region for a composite treatment plan, where the 'composite' fluence across the chamber becomes uniform, the overall measurement uncertainty was minimized (Leybovich et al 2003) . The procedure was repeated for all 52 IMRT plans included in this study.
For benchmarking MUV, doses were recalculated in specific points in the respective verification phantom. DICOM RT files exported directly from the TPS were used as patientspecific input data. Thus, all information for an independent calculation (MU per segment, leaf and collimator settings, energy, position of dose specification point) was automatically transferred from the TPS to MUV. The phantoms, including their density and dimensions, were implemented in the verification software and could be selected from a local phantom database. Point dose calculations at the location of the IC were repeated with the MUV software for all composite treatment plans. Additionally, point dose calculations of single IMB were compared against IC measurements for a large fraction of IMB.
For the 15 head-and-neck IMRT plans with a SIB, results from TPS and MUV were also compared for multiple points located in the second and/or third prescription dose level, in OARs and in the low dose region. Points of interest were selected in such a way that a comparison with film dosimetry was possible.
QA workload
The total time for experimental IMRT verification in solid phantoms, based on film and IC measurements, was compared with the calculation-based approach in a minimum of five arbitrary points. Therefore, the necessity for patient-specific and treatment-machine-related procedures was reanalysed. Within this context, the workload associated with one or the other techniques was summarized based on the departments' experience.
Results
Composite treatment plans
For composite IMRT plans, average deviations in the high dose region between IC measurements and point dose calculations performed with the TPS and MUV were 1.6 ± 1.2% (1 S.D.) 5 and 0.5 ± 1.1%, respectively. In general, with Oncentra Masterplan slightly smaller deviations were observed than with Helax TMS. These deviations correspond to 3.2 ± 2.4 cGy and 1.0 ± 2.2 cGy per fraction.
All 52 IMRT plans were verified with EDR-2 type films and fulfilled the in-house-defined acceptance criteria based on the gamma index (Stock et al 2005) . The criteria were based on a 4% dose difference and 3 mm distance to agreement tolerances. The mean γ >1 , γ mean , γ 1% were 5.7% ± 4.7%, 0.42 ± 0.09 and 1.38 ± 0.31, respectively.
For the five IMRT head-and-neck plans with a SIB, representing the most complex IMRT technique involved in our study, arbitrary dose profiles were calculated in the homogeneous phantom in a plane that included the isocentre. A grid spacing of 0.5 cm was used and the line covered points up to 12 cm from the centre of the phantom. The average deviations (∼300 calculation points) between the MUV and the TPS were small, −0.1 ± 0.4 cGy when applying a pencil beam model (PB) in the TPS and 0.2 ± 0.4 cGy when using the collapsed cone (CC) algorithm. Figure 1 shows typical results of line dose calculations and measurements for a head-and-neck case with a SIB containing three dose levels.
Dose deviations between MUV and TPS calculations slightly depended on distance from the isocentre position. Figure 2 presents relative dose deviations as a function of distance from the isocentre for head-and-neck IMRT plans with SIB. 89% of the verified points were within a 3% tolerance limit and the largest deviations (∼6%) refer to 50% isodose regions. In absolute dose, 99% of all deviations were smaller than 10 cGy and 75% smaller than 5 cGy. At reference dose points located in the centre of the phantom, there was an average deviation of 2.2% between the TPS PB model and MUV for head-and-neck plans with SIB. For pelvic treatments, this deviation was only 1%. Table 1 summarizes absolute and relative dose deviations in points located in predefined regions of interest for 15 head-and-neck IMRT patients receiving a SIB technique. Results obtained through the PB algorithm of the TPS were used as reference. This reflects the focus towards the TPS PB data, as this algorithm is still the one most frequently applied in daily clinical practice.
The agreement between film measurements and calculations at off-axis points located in OAR (in the original treatment plan) or in the low dose region was compromised by the overall accuracy that can be obtained with film dosimetry (Gillis et al 2005) . The largest deviations between film measurements and PB calculations (TPS) were around 15 cGy for points of interest located in OARs or in low dose regions. Maximum deviations between TPS PB calculations and those performed with MUV were slightly smaller (between 5 and 8 cGy).
Individual IMB verification
When analysing the plans on a field-by-field basis, an average deviation of 1.1 ± 2.9% was determined, with a maximum deviation of 14%. However, absolute deviations per beam were mostly below 3 cGy, with a mean deviation of only 0.3 ± 0.8 cGy. Figure 3 shows relative deviations between MUV and TPS calculations (in the verification phantom) in the dose specification point, while figure 4 shows corresponding absolute deviations in cGy. The average deviation around 2 cGy for composite plans between TPS and MUV compares well with the average deviation per beam, as most treatment plans consisted of seven IMB.
Average deviations between a restricted number of IMB (∼100 arbitrarily selected from the database), IC measurements and point dose calculations performed with the TPS were −1.9 ± 2.3% (1 S.D.), with maximum deviations around 8%. Again, measurement points for single field measurements were located in the high dose region. When comparing these IC measurements and calculation performed with MUV, the respective values were −0.8 ± 2.2% (1 S.D.), with maximum deviations around 5%. 1.8 ± 2.9 2.6 ± 2.3 3.0 ± 1.6 0.8 ± 1.3 1.2 ± 1.0 1.4 ± 0.7 0.8 ± 1.3 1.2 ± 1.0 1.4 ± 0.7
Second prescription dose level for a SIB −0.6 ± 3.5 −0.2 ± 5.0 2.1 ± 1.4 −0.4 ± 2.1 −0.2 ± 2.9 1.3 ± 0.8 −0.3 ± 1.6 −0.1 ± 2.2 1.0 ± 0.6 OAR 0.2 ± 3.8 −1.6 ± 14.5 2.3 ± 1.1 0.9 ± 3.2 −0.9 ± 12.4 1.8 ± 0.9 0.1 ± 1.7 −0.8 ± 6.6 1.0 ± 0.5 Low dose region −3.5 ± 3.0 −3.9 ± 6.2 0.6 ± 0.8 −5.2 ± 4.3 −6.3 ± 9.4 0.8 ± 1.2 −1.6 ± 1.4 −1.8 ± 2.9 0.3 ± 0.4 
QA workload
The total time needed for an independent calculation in five verification points was less than 10 min per IMRT plan, including the DICOM file export from the TPS and import into the MUV software and data recording. This time compares very favourably with the net time of several hours for an experimental approach. Table 2 lists QA tasks and associated net time estimates for patient-specific IMRT verification, based on the experience of two departments (Umeå University and the Medical University Vienna). In addition to the time saving factor of about 4 to 5, no extra time on the linac is required. This is, however, to some extent counterbalanced by the additional QA procedures for the MLC. If we assume four new IMRT treatments per week, the patientspecific QA with MUV can be easily performed within one afternoon. In contrast, experimental verification would need more than 12 h, in which the linac partly cannot be used for treatments.
Discussion
A rigorous QA procedure is required to ensure that the dose distribution planned on an IMRT treatment planning system will be delivered safely and accurately. For any treatment technique, MUs for a given treatment plan correlate the planned dose and the actual dose delivered to the patient. Therefore, independent dose or MU verification is considered as a very important patient-specific QA procedure. In 3D conformal radiotherapy MU checks in a single point are generally considered to be sufficient, as the uniform fluence pattern spatially correlates the dose in multiple points. For IMRT it can be argued that dose verification in a single point is no longer sufficient due to its increased complexity. On the other hand, factor-based methods cannot provide a sufficiently high accuracy for IMRT dose verification, e.g. near OARs. It has, therefore, become of practice to verify IMRT treatment plans through experimental 2D approaches (e.g. Ezzell et al 2003 , Gillis et al 2005 , Wiezorek et al 2005 .
With an increasing number of IMRT patients, it is important to have access to efficient and accurate QA tools. If only patient-specific QA is performed through random selection, rather than for each patient, the gain expected from IMRT may be lost due to unintentional non-optimal dose delivery. Independent dose calculations for IMRT are an important, but today often missing link in the chain of rigorous QA for IMRT applications. When applying such verification calculations, there are a few aspects that need closer consideration.
Firstly, deviations should be considered in absolute as well as relative terms. Similar to our results, large relative deviations have been found by other groups (Baker et al 2006 , Chen et al 2002 , Linthout et al 2004 , predominantly in areas outside the high dose region which is largely affected by collimator transmission and penumbra modelling.
Based on the results obtained in this benchmark study, we aim to apply a confidence limit of 3% dose deviation (with respect to the prescribed dose) or 6 cGy for full IMRT plans and individual points close to the isocentre. As long as individual points of interest close to the isocentre are considered, we apply the same criteria to targets and OARs. For off-axis points at distances 5 cm or low dose regions, we consider 5% dose deviation or 10 cGy acceptable. For these considerations, the confidence limit concept proposed by Venselaar et al (2001) was applied. Currently, our clinical practice for IMRT verification is based on independent dose calculations in at least five points of interest. The points cover the high dose region(s) in the PTV(s), dose regions with 50-70% of the prescribed dose outside the target, as well as the low dose region. Clinical practice, however, depends on the software feature of the verification tool. The research version of MUV did not contain automated profile dose or isodose calculations, calculations in 2D or 3D calculations in a volume. Such features, combined with gamma evaluation tools, would offer a very powerful tool for dose comparisons.
Secondly, calculations performed with independent algorithms are typically performed in a flat homogeneous (water) phantom for individual beams or in a homogeneous verification phantom for composite IMRT plans. Current work on verification dose calculations for QA purposes focus primarily on beam-oriented models and related input data. Anatomic information and inhomogeneities are in most cases not considered. As an exception, the independent dose calculation approach presented by Chen et al (2002) for serial tomotherapy included at least the external patient contour. Further research is needed to explore whether the ultimate goal, a full 3D verification calculation based on the patient CT data set, brings any advantage over recalculations in a homogeneous verification phantom.
Thirdly, when performing independent dose calculations for IMRT verification the data transfer from the TPS to the linac and the performance of the delivery unit is not checked. Thus, a more stringent machine and MLC QA need to be considered. If data transfer and linac/MLC performance are to be included in the QA chain, one option for an automated process would be to measure MLC settings and monitor units for each segment with an EPID and use these geometric and dosimetric information for an independent IMRT verification calculation or an EPID-based in vivo approach (Winkler et al 2005 , Wendling et al 2006 .
Finally, the accuracy of the independent dose calculation algorithm (or software) itself is critical. The algorithms in MUV were thus developed primarily for high dose calculation accuracy and not for speed. For example, the trend of dose deviations presented in figure 2 results from off-axis softening modelled in MUV and CC, but not in the PB model (Ahnesjö et al 2005 , Olofsson et al 2006b . Off-axis softening is a function of both depth and off-axis distance and can amount to roughly 5% in local dose difference (Olofsson et al 2006b) .
Conclusion
The physical effects modelled in the independent dose calculation software MUV allow doses to be calculated in individual points in a homogeneous phantom very accurately, also for IMRT plans. Independent dose calculation is an efficient method for patient-specific QA in IMRT once the IMRT programme is mature. Nevertheless, during the commissioning and start-up phase of IMRT experimental verification methods cannot be replaced in a rigorous IMRT QA programme.
